GE

Biogen Idec, Isis partner on antisense program targeting myotonic dystrophy

Friday, June 29, 2012 03:12 PM

Weston, Mass.-based Biogen Idec and Isis Pharmaceuticals of Carlsbad, Calif., have entered into an exclusive, worldwide option and collaboration agreement to develop and commercialize a novel antisense drug for the treatment of myotonic dystrophy type 1 (DM1), also known as Steinert disease.

More... »

GSK further extends HGS tender offer

Friday, June 29, 2012 02:14 PM

GlaxoSmithKline has extended its tender offer to acquire all of the outstanding shares of Human Genome Sciences for $13.00 per share in cash to 5:00 p.m. EST on July 20, 2012.

More... »

Quotient Clinical, Capsugel collaborate on lipid-based formulations

Friday, June 29, 2012 11:23 AM

Quotient Clinical, a U.K. provider of specialist early stage drug development services, and Capsugel, a Morristown, N.J.-based provider of dosage solutions for the healthcare industry, have formed a collaboration to enable the rapid development and clinical assessment of lipid-based formulations. Together, the companies will use their technology and expertise to address the drug delivery challenges of poorly soluble molecules with limited oral bioavailability.

More... »

Merge releases eClinical OS platform

Thursday, June 28, 2012 11:33 AM

Merge Healthcare, a Chicago-based provider of clinical systems and innovations that seek to transform healthcare, has released Merge eClinical OS, a new clinical trial operating solution that provides first-of-its-kind, end-to-end study support for trials of all sizes through one interface, one consistent experience, one platform.

More... »

Roche to streamline R&D activities, close New Jersey site

Wednesday, June 27, 2012 10:46 AM

Roche has decided to consolidate activities within its research and early development division, resulting in the closure of the company’s Nutley, N.J., site. Research and development activities will be consolidated at the existing sites in Germany and Switzerland, focusing on oncology, virology, metabolism and neuroscience.

More... »

Soligenix, IDRI to develop thermostabilized biodefense vaccines

Wednesday, June 27, 2012 09:44 AM

Soligenix, a development stage biopharmaceutical company, has entered into a collaboration with the Infectious Disease Research Institute (IDRI) of Seattle, Wash., to develop select biodefense vaccines using IDRI's potent and safe synthetic adjuvants in conjunction with Soligenix's proprietary subunit proteins and thermostability platform, ThermoVax. 

More... »

Amgen, actress Maura Tierney launch ‘Chemotherapy: Myths or Facts’ campaign

Monday, June 25, 2012 03:30 PM

Amgen, a biotech based in Thousand Oaks, Calif., has launched Chemotherapy: Myths or Facts, an awareness campaign for cancer patients and their caregivers featuring Emmy-nominated actress and breast cancer survivor Maura Tierney.

More... »

Merck Serono, Compugen establish new biomarker company Neviah Genomics

Monday, June 25, 2012 02:52 PM

Merck Serono of Darmstadt, Germany, and Compugen, a therapeutic product discovery company of Tel Aviv, Israel, have established a novel start-up company called Neviah Genomics, focused on the discovery and development of novel biomarkers for the prediction of drug-induced toxicity.

More... »

CRA honored with 5 STEVIE Awards

Friday, June 22, 2012 02:05 PM

Tempe, Ariz.-based Clinical Research Advantage, a community-based network of clinical trial sites, was honored with three silver and two bronze STEVIE Awards at the 10th Annual American Business Awards on June 18. 

More... »

West Pharmaceutical signs tech agreement with Amgen

Thursday, June 21, 2012 02:42 PM

West Pharmaceutical Services, a global manufacturer of components and systems for injectable drug delivery, has signed an agreement with Amgen, an independent biotech based in Thousand Oaks, Calif., to evaluate Daikyo Crystal Zenith technologies for drug containment.

More... »